Menu
1 min read · estimated
APPROVED USE
What FDA approved
Clarifies the existing use to adults with advanced renal cell carcinoma that has a clear-cell component following prior PD-1 or PD-L1 inhibition and VEGF tyrosine kinase inhibitor therapy.
LAMPGEN ANALYSIS
Why it matters
The revised label explicitly identifies the histology represented by the pivotal evidence.
What research teams should watch
Confirm the clear-cell component and both prior drug classes before using the revised eligibility criteria.
PRIMARY RECORDS